13 research outputs found

    Public Health Laboratories: Unprepared and Overwhelmed

    Get PDF
    Addresses the role of public health labs within the public health system and their ability to respond to specific chemical weapon events. Provides recommendations for improving response to terrorism as well as more conventional threats

    Ready or Not? Protecting the Public's Health in the Age of Bioterrorism, 2004

    Get PDF
    Examines ten key indicators to evaluate state preparedness to respond to bioterrorist attacks and other public health emergencies. Evaluates the federal government's role and performance, and offers recommendations for improving readiness

    F as in Fat: How Obesity Policies Are Failing in America, 2005

    Get PDF
    Examines national and state obesity rates and government policies. Challenges the research community to focus on major research questions to inform policy decisions, and policymakers to pursue actions to combat the obesity crisis

    F as in Fat: How Obesity Policies Are Failing in America, 2004

    Get PDF
    Examines national and state obesity rates and government policies. Focuses on setting a baseline of current policies and programs, and offers a comprehensive look at their range and quality

    Ready or Not? Protecting the Public's Health in the Age of Bioterrorism, 2005

    Get PDF
    Examines ten key indicators to evaluate state preparedness to respond to bioterrorist attacks and other public health emergencies. Evaluates the federal government's role and performance, and offers recommendations for improving readiness

    Shortchanging America's Health: A State-by-State Look at How Federal Public Health Dollars Are Spent

    Get PDF
    Examines the allocation of federal health funds to emphasize that the U.S. is falling short on achieving federally established goals for reducing disease and improving health. Calls for a proactive approach, focusing on prevention of illness and injury

    Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

    Get PDF
    Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≄ II, EF ≀35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure < 100 mmHg (n = 1127), estimated glomerular filtration rate < 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation

    Improving Cancer Tracking Today Saves Lives Tomorrow: Do States Make the Grade?

    No full text
    Describes successes in the fight against cancer that tracking has helped to achieve. Evaluates how well states are doing in their efforts to track, control, and prevent cancer and awards grades on a state-by-state basis. Provides recommendations
    corecore